Treating postmenopausal osteoporosis in women at increased risk of fracture – critical appraisal of bazedoxifene: a review
Peter Vestergaard, Susanna vid Streym ThomsenDepartment of Endocrinology and Metabolism C, Aarhus University Hospital, Aarhus, DenmarkAbstract: Several categories of drugs to treat osteoporosis exist in the form of bisphosphonates, strontium, parathyroid hormone, and selective estrogen receptor modu...
Main Authors: | Peter Vestergaard, Susanna vid Streym Thomsen |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-08-01
|
Series: | International Journal of Women's Health |
Online Access: | http://www.dovepress.com/treating-postmenopausal-osteoporosis-in-women-at-increased-risk-of-fra-a3457 |
Similar Items
-
Bazedoxifene for the prevention of postmenopausal osteoporosis
by: Luigi Gennari, et al.
Published: (2008-09-01) -
Efficacy and safety of bazedoxifene for postmenopausal osteoporosis
by: Kawate H, et al.
Published: (2011-06-01) -
Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis
by: Palacios Santiago, et al.
Published: (2010-06-01) -
Profile of bazedoxifene/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture
by: Rossini M, et al.
Published: (2013-07-01) -
Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal
by: Roberto Cesareo, et al.
Published: (2009-12-01)